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Abstract
Background: The National Institute for Health and Care Excellence (NICE) recommends evidence-based parenting
programmes as a first-line intervention for conduct disorders (CD) in children aged 5–11 years. As these are not
effective in 25–33% of cases, NICE has requested research into second-line interventions. Child and Adolescent
Psychotherapists (CAPTs) address highly complex problems where first-line treatments have failed and there have
been small-scale studies of Psychoanalytic Child Psychotherapy (PCP) for CD. A feasibility trial is needed to
determine whether a confirmatory trial of manualised PCP (mPCP) versus Treatment as Usual (TaU) for CD is
practicable or needs refinement. The aim of this paper is to publish the abridged protocol of this feasibility trial.
Methods and design: TIGA-CUB (Trial on improving Inter-Generational Attachment for Children Undergoing
Behaviour problems) is a two-arm, pragmatic, parallel-group, multicentre, individually randomised (1:1) controlled
feasibility trial (target n = 60) with blinded outcome assessment (at 4 and 8 months), which aims to develop an
optimum practicable protocol for a confirmatory, pragmatic, randomised controlled trial (RCT) (primary outcome:
child’s behaviour; secondary outcomes: parental reflective functioning and mental health, child and parent quality
of life), comparing mPCP and TaU as second-line treatments for children aged 5–11 years with treatment-resistant
CD and inter-generational attachment difficulties, and for their primary carers. Child-primary carer dyads will be
recruited following a referral to, or re-referral within, National Health Service (NHS) Child and Adolescent Mental
Health Services (CAMHS) after an unsuccessful first-line parenting intervention. PCP will be delivered by qualified
CAPTs working in routine NHS clinical practice, using a trial-specific PCP manual (a brief version of established PCP
clinical practice). Outcomes are: (1) feasibility of recruitment methods, (2) uptake and follow-up rates, (3) therapeutic
delivery, treatment retention and attendance, intervention adherence rates, (4) follow-up data collection, and
(5) statistical, health economics, process evaluation, and qualitative outcomes.
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Discussion: TIGA-CUB will provide important information on the feasibility and potential challenges of undertaking
a confirmatory RCT to evaluate the effectiveness and cost-effectiveness of mPCP.
Trial registration: Current Controlled Trials, ID: ISRCTN86725795. Registered on 31 May 2016.
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Background
Conduct disorders (CD) are ‘repetitive and persistent
patterns of antisocial, aggressive or defiant behaviour that
amount to significant and persistent violations of age-
appropriate social expectations’ [1]. They affect 5% of 5–
10-year-olds (187,500 children in England and Wales,
based on 2011 census data), with prevalence expected to
rise [2, 3]. Pre-adolescent CD risk particularly adverse out-
comes, including poor educational achievement, teenage
pregnancy, substance abuse, criminality, long-term phys-
ical and mental illness, unemployment, homelessness, do-
mestic violence, and poor subsequent parenting [4–13].
Children’s CD impact substantially on the NHS, constitut-
ing 30% of GP child consultations and 45% of child com-
munity health referrals [1]. Long-term public service costs
can be ten times higher (£70 k) for those with childhood
CD than for those without, and related crime costs £22.5
billion annually [14–18]. CD are, therefore, an important,
expensive, and growing problem.
There is clear evidence that many parenting pro-
grammes deliver effective outcomes [1]. However, our
scoping study, funded by the National Institute of Health
Research (NIHR) Flexibility and Sustainability Funding
(FSF) and conducted in five Child and Adolescent
Mental Health Services (CAMHS) (n = 145)(Edginton E,
Twiddy M. Scoping study in regional CAMHS in the north
of England on children aged 5-11 with conduct disorders,
unpublished) showed that evidence-based protocols are
often not followed. Children and Young People’s Improving
Access to Psychological Therapies (CYP-IAPT – a national
programme which aims to develop an improved CAMHS)
should help with this, but even evidence-based programmes
do not benefit 25–33% of families, and 30–40% drop out
[1, 19, 20]. The long-term costs of treatment-resistant CD
are extremely high, and if parent training fails, there are
few alternatives. Cognitive-behavioural and/or social
learning programmes are only recommended for children
aged 9+ years [1], and multisystemic interventions only
for children aged 11+ years [1]. These options either in-
volve a major component of parent training, which will
already have failed for our intended patient group, or
demonstrate small effect sizes, suggesting that these op-
tions will be unsuitable for treatment-resistant CD, or are
more resource-intensive and intended for older children
[1]. National Institute for Health and Care Excellence
(NICE) has, therefore, requested research on urgently
needed, second-line treatments [1].
Psychoanalytic Child Psychotherapy (PCP) for
treatment-resistant CD is supported by theoretical and
pragmatic research as well as by clinical experience.
Large meta-analyses on links between attachment and
children’s CD have found correlations between insecure
(and particularly, disorganised) attachment and subse-
quent behaviour problems [21–24]. Other studies have
found links between children’s CD and primary-carer
(particularly maternal) attachment difficulties [25–28],
and between children’s disorganised attachment and par-
ental trauma [29]. Both secure and insecure attachment
are liable to inter-generational transmission [29], with
one meta-analysis finding a match between mother and
child secure-insecure attachment styles of 75% (κ = .49)
[30]. In our scoping study of children with behaviour dif-
ficulties in CAMHS, 60% of mothers indicated potential
inter-generational attachment difficulties (Edginton E,
Twiddy M. Scoping study in regional CAMHS in the
north of England on children aged 5-11 with conduct
disorders, unpublished). These are linked to problems in
reflective functioning, i.e. understanding behaviour in
terms of underlying thoughts and feelings [31, 32], and
to adult mental health problems [33, 34], which can con-
tribute to children’s CD [1, 35]. Nevertheless, secure at-
tachment can be ‘earned’ via positive experiences post
infancy [36–38]. Child and Adolescent Psychotherapists'
(CAPTs’) clinical experience that families of children
with CD often have inter-generational attachment diffi-
culties is thus endorsed by both theoretical and empir-
ical research.
It is widely accepted that CAPTs address highly complex
problems – including inter-generational attachment diffi-
culties – where first-line treatments have failed [39, 40].
CAPTs are trained to work with children and their pri-
mary carers, to recognise adult mental health difficulties,
and to refer parents/carers to GPs and adult services,
where appropriate [41]. There have been several small
studies of PCP for CD. A retrospective study of children
in intensive and non-intensive psychotherapy (n = 763) in-
cluding children with CD found that 49% of children over-
all made clinically significant improvements in levels of
functioning on the Hampstead Child Adaptation Measure
(HCAM) [42], while a retrospective case-control study
Edginton et al. Trials  (2017) 18:431 Page 2 of 16
comparing children with a disruptive disorder (n = 135)
and those with an emotional disorder found significant
improvement in functioning in both the disruptive and
emotionally disordered groups [43]. A naturalistic study
(n = 9) found similar improvements in overall functioning
and externalising behaviour using the Global Assessment
of Functioning scale (GAF) and the Child Behavior Check-
list (CBCL) and CBCL Teacher Report Form (CBCL-TRF)
[44]. A controlled trial (n = 26) resulted in clinically
significant improvements on the Impairment Score for
Children and Adolescents (IS-CA) in 31% of children,
compared with 8% in the waiting list control, but no sig-
nificant difference on the CBCL [45]. A randomised con-
trolled trial (RCT) (n = 69) found Family Therapy and
Child Psychotherapy equally superior to the recreational
control treatment group using the CBCL [46]. However,
these studies all had small samples and were not con-
ducted in UK CAMHS.
The PCP intervention used in the TIGA-CUB (Trial
on improving Inter-Generational Attachment for
Children Undergoing Behaviour problems) feasibility
study is a systematic, manualised, brief version of exist-
ing clinical practice. It comprises 12 sessions for the
child and 12 sessions for the primary carer (and any
other of the child’s parents/carers who wish to attend).
The term ‘primary carer’ denotes the adult – i.e. parent
or kinship carer – the parents/carers consider to be the
most involved in parenting the child. The ‘change hy-
pothesis’ is that a regular, predictable, and intensive posi-
tive attachment experience with the CAPT for the child
is likely directly to improve the child’s behaviour, and
that direct work with the primary carer and any other
parent/kinship carer who wishes to attend is likely to en-
hance parental reflective functioning [47, 48], improving
understanding of the emotional distress that the child is
communicating via the problematic behaviour [44, 49].
The work is also likely to empower primary carers,
making them feel less stressed, and to help them gain
greater control over parenting behaviour through un-
derstanding their own experiences of having been par-
ented and of how their child’s behaviour might trigger
their own complex and possibly traumatic childhood
memories [50]. The intervention might also begin to
assist primary carers to acknowledge mental health dif-
ficulties and to access adult services, where appropriate
[40]. It is anticipated that primary carer benefits will re-
sult in a more sympathetic approach to the child to
which the child will respond, thereby promoting a posi-
tive cycle of change.
This paper describes the protocol for the feasibility
trial evaluating manualised Psychoanalytic Child Psy-
chotherapy (mPCP) compared with Treatment as Usual
(TaU) within CAMHS. In the absence of a clear evi-
dence base at the time of our scoping study and when
funding was obtained, TaU tended to be highly hetero-
geneous, including interventions which ranged from
generic non-specific parent or child work and paren-
ting programmes through to Play Therapy, Family
Therapy, and non-manualised, long-term PCP. Our
comparator is, therefore, heterogeneous TaU rather
than a specific, homogeneous alternative, both because
the latter is not currently practicable in CAMHS, and
because one or even two comparators would answer
the explanatory, but not the pragmatic, question of
interest to the NHS.
Aims and objectives
The aims of this trial are:
1. To assess the feasibility of conducting, and
2. To inform the design of, a large-scale, confirmatory
RCT of second-line mPCP versus TaU for children
aged 5–11 years with treatment-resistant CD and
their primary carers, so as to improve the range of
treatment options and long-term outcomes for this
hard-to-treat patient group.
The objectives of the trial are:
1. To establish procedures for screening children
referred to, or re-referred within, CAMHS with CD
and their primary carers, and to estimate the
recruitment rate and the proportion of primary
carers with mental health difficulties
2. To assess acceptability to clinicians and primary
carers of randomising to mPCP or TaU.
3. To collect baseline and 4-month blinded follow-up
data (and 8-month follow-up data for those
recruited in the first 4 months of the trial), to
estimate likely follow-up rates and data quality for
the confirmatory trial
4. To collect data on treatments received within
CAMHS across trial arms to characterise
co-interventions and TaU over time
5. To assess the feasibility of, and best methods for,
collecting data from various sources (primary carers,
children, and teachers), including national routine
data sets as they become available during the
lifetime of the trial
6. To assess the feasibility of, and best methods for,
collecting adverse events relating to the child or
primary carer
7. To identify the most appropriate way to collect
quality of life and cost data to assess short and
long-term cost-effectiveness
8. To assess the feasibility of keeping researchers blinded,
by monitoring the rate and reasons for unblinding
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9. To establish procedures for assessing treatment
attendance and adherence to the intervention
10.To confirm the variability and clustering of
outcomes by clinician to inform sample size
calculations for the confirmatory trial.
The full protocol (version 3.2, 20 April 2017) is
available on request from the corresponding author.
Methods and design
Design
TIGA-CUB is a multicentre, two-arm, pragmatic, parallel-
group, individually randomised controlled feasibility trial.
A summary of the trial design is included as a flow dia-
gram below (see Fig. 1).
Setting
CAMHS in (1) Bradford and Keighley, (2) Dudley and
Walsall, (3) Sheffield, and (4) Wakefield and Castleford
were selected to participate to maximise generalisability
and to provide a good test of the feasibility of recruit-
ment. Service configurations vary considerably across
these settings, with all CAMHS using a triage system on
first referral, but with different subsequent internal path-
ways, and with some CAMHS having only one CAPT
while others have up to five.
Eligibility criteria
Participant eligibility will be assessed in stages. Inclusion
and exclusion criteria will first be assessed by CAMHS
practitioners involved in screening referrals. The final
two exclusion criteria (primary-carer alcohol and drug
dependence) will be assessed by the researcher when
contacting participants who have consented to re-
searcher contact, as will confirmation of a clinical level
of CD.
Inclusion criteria:
 Child aged 5–11 years old at baseline
 Presenting to CAMHS, or re-referred within
CAMHS, with a clinical level of CD ≥ 4 on the
Strengths and Difficulties Questionnaire (SDQ) [51]
conduct subscale
 Child’s current primary carer has been offered a
first-line group or individual parenting programme
or other structured parenting intervention in
primary care or within CAMHS, involving a series
of structured sessions focussing on parenting and/or
child behaviour management techniques, and has
attended at least one session, but the child’s CD
persists and the child has been referred to CAMHS
or re-referred within CAMHS for further treatment.
Exclusion criteria:
 Child with a clinical diagnosis of autistic spectrum
disorder (ASD), including Asperger’s syndrome
 Child with a clinical diagnosis of severe learning
difficulties (LD)
 Child medicated for attention deficit hyperactivity
disorder (ADHD), unless they have been on a stable
medication dose for 3 months or more (children
with un-medicated ADHD are eligible if other
inclusion criteria are met)
 Looked After Child (LAC), unless they are in a
stable (at least 6 months) kinship adoption, kinship
foster care or kinship special guardianship
relationship with their carer
 Child under/at risk of safeguarding or court procedures
 Child whose primary carer has severe mental health
difficulties, determined by usual CAMHS procedures
using clinical judgement (baseline General Health
Questionnaire (GHQ-12) [52] will be monitored for
primary carers with severe mental health difficulties
not identified by CAMHS)
 Sibling has been randomised to TIGA-CUB
(avoidance of potential contamination)
 Primary carer is actively receiving a parenting
programme within CAMHS for the child’s sibling
 Primary carer lacks capacity to comply with trial
requirements, e.g. as a result of a LD, or due to
insufficient proficiency in English
 Primary carer is currently participating in another
research project that would mean participation in
TIGA-CUB would be too burdensome
 Primary carer has severe adverse parental
functioning, e.g. alcohol dependence (≥20 on
Alcohol-Use Disorders Identification Test)
(AUDIT-C) [53] or drug dependence (≥ 3 on the Drug
Abuse Screening Test) (DAST-10) [54], determined
by the trial researcher on initial screening visit.
Participant identification and recruitment
Due to CAPT clinical practice and availability, it is antici-
pated that recruitment will take place in line with school
terms and half terms where possible, resulting in recruit-
ment of up to five cohorts of participant dyads during the
recruitment period. Recruitment will be initiated after re-
ferral to, or re-referral within, CAMHS. All referrals aged
between 5 and 11 years with a potential CD will be
screened. Once a potential primary carer-child dyad has
been identified and CAPT capacity has been confirmed,
the local CAMHS practitioner will introduce the trial to
them. If the primary carer is interested in participating,
the primary carer and child will be provided with TIGA-
CUB Information Leaflets and consent will be gained for
initial researcher contact. In addition, as part of the
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process evaluation for the trial, primary carers will receive
a questionnaire gauging their understanding of the trial
and asking about their views on the recruitment process,
and will be asked if they would be willing to consent to a
process evaluation researcher contacting them subse-
quently to collect more detailed feedback. Responses will
be reviewed so that recruitment processes can be refined
for a confirmatory trial.
Where consent is given for initial researcher contact,
the primary carer will be contacted and a meeting
scheduled either at the primary carer’s home or at an-
other appropriate location to explain the trial in greater
detail, establish full trial eligibility, obtain consent, and
undertake the baseline assessment. The dyad will have
been given at least 24 h to read and digest the Informa-
tion Leaflets previously provided, and will have had the
Fig. 1 TIGA-CUB trial flow diagram
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opportunity to discuss them with their family and/or
other health care professionals (e.g. GP) if they so wish,
before being asked whether they would be willing to take
part in the trial.
All primary carers will be asked to complete the AUDIT-
C and DAST-10, plus the SDQ. Formal consent will not be
required prior to completion of these measures, as comple-
tion will constitute implied consent. Those who decline at
this stage will be offered TaU for their child. Those who
complete these measures but score outside of the thre-
sholds specified in the inclusion criteria will not be eligible
to take part, and will also be offered TaU.
Where dyads fulfil all the eligibility criteria, the pri-
mary carer will be invited to provide informed written
consent. Given the age of the children involved in the
trial (5–11 years old), their formal consent will not be
obtained, and the primary carer will provide consent for
their inclusion. However, as per the Health Research
Authority (HRA) guidance for research involving chil-
dren, children will still be involved in the decision-
making process with the right to voice their views and
to influence the resulting decision, and will be provided
with information that matches their capacity. Should the
child actively object to taking part in the trial, then they
will not be included, and reasons for non-participation
will be recorded, where provided.
Randomisation
Following confirmation of eligibility and consent, and sub-
sequent to the baseline assessment being performed, dyads
will be randomised by the trial researcher via the Clinical
Trials Research Unit’s) (CTRU’s) automated 24-h random-
isation system. Dyads will be randomised (1:1 basis) to re-
ceive mPCP or TaU. A computer-generated minimisation
algorithm incorporating a random element will be used,
stratifying for (1) site and (2) gender of child. If a dyad is
randomised to mPCP in a CAMHS clinic in which multiple
CAPTs are available to deliver the intervention, dyads will
also be randomly allocated to the CAPT who will deliver
the child’s intervention, with an allocation ratio propor-
tional to CAPT availability, to avoid selection bias. Where
only one CAPT works in a CAMHS, the CAPT will auto-
matically be selected as the delivering CAPT. The CTRU
will inform the CAMHS, but not the researcher (to pre-
serve blinding), of the outcome of randomisation. The
CAMHS will contact the primary carer to explain the out-
come of the randomisation and to make an appointment
for initiation of treatment. Therefore, participants and
CAPTs will, of necessity, be aware of treatment allocation.
Interventions
Manualised Psychoanalytic Child Psychotherapy (mPCP)
Qualified CAPTs who are current members of the
Association of Child Psychotherapists (ACP), working in
CAMHS, and trained in the trial intervention will deliver
mPCP (referring to both sessions for the child and work
with the primary carer and any other of the child’s par-
ents/carers wishing to attend), using the TIGA-CUB
manual. The manual is sufficiently flexible to accommo-
date the range of situations likely to be encountered in
the trial, and will be reviewed (and updated if necessary)
at the end of the feasibility trial by the Trial Management
Group (TMG) to ensure that it is appropriate for a con-
firmatory trial.
Children will attend mPCP sessions of approximately
50-min duration each, delivered over 12 weeks at ap-
proximately weekly intervals (excluding breaks of no
more than 2 weeks at normal school holidays). This will
equate to a total of up to 12 sessions. The primary carer
will attend parent work sessions of similar number, dur-
ation, and spacing. It is planned that the child and pri-
mary carer, respectively, will be seen separately either by
the same CAPT or by two different CAPTs. The reason
for this decision will be recorded. Where the child and
primary carer are seen by the same CAPT, the sessions
will, of necessity, take place at different times, but will
take place in the same week as far as is practically pos-
sible. If the child and primary carer are seen by two dif-
ferent CAPTs, the sessions will either take place at the
same time, or will take place at different times within
the same week, where possible. Where the child and pri-
mary carer are seen by two different CAPTs at different
times, the primary carer sessions will commence prior to
those of the child. Following PCP practice, the day, time,
and location of all sessions will be kept consistent unless
there are exceptional circumstances, and the interven-
tion will usually commence no less than 3 weeks prior
to an end-of-term or half-term break so as to facilitate
the establishment of the therapeutic alliance. A holiday
break will nevertheless be incorporated where possible,
to give the child and primary carer a ‘practice run’ at a
therapeutic ending.
As with TaU, it is anticipated that some participants
will miss sessions because of dropout (intermittent or
complete) or mutually agreed early termination of treat-
ment. Conversely, some may go on to receive more
sessions, where this is deemed clinically appropriate, al-
though it is anticipated that this will be the exception ra-
ther than the rule. In line with usual CAMHS practice,
each local CAMHS will identify a named case manager
for the CAPT(s) to liaise with, to provide assurance with
regard to clinical governance.
All eligible CAPTs working within a recruiting CAMHS
will be trained and supervised to deliver mPCP in the trial.
CAPTs will receive appropriate training in the use of the
manual and adherence to it, delivered by the chief investi-
gator, and other relevant members of the TMG if neces-
sary. Small-group supervision of participating CAPTs will
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be conducted approximately fortnightly, in person except
in exceptional circumstances, by supervisors experienced
in working with children with CD and in the use of the
manual who will themselves attend termly supervision, to
facilitate adherence to the manual and quality of care.
Supervising CAPTs will be trained by appropriate mem-
bers of the TMG. These arrangements will ensure a fair
test of mPCP by using qualified CAPTs receiving regular
clinical supervision, which is accepted best practice in
CAMHS and in the ACP.
Treatment as Usual (TaU)
TaU will comprise the usual care offered by local
CAMHS to children aged 5–11 years with CD. This
treatment is likely to be highly diverse and may involve
group and/or individual child and/or primary carer and/
or family based work, delivered by a range of practi-
tioners from a variety of professional backgrounds and
theoretical orientations. The duration of TaU in CAMHS
will vary considerably, but our scoping study demon-
strated that the average amount of time spent in
CAMHS is likely to be at least 33 weeks (Edginton, E,
Twiddy, M. Scoping study in regional CAMHS in the
north of England on children aged 5-11 with conduct
disorders, unpublished). The confirmatory trial will be
pragmatic, involving several collaborating CAMHS, and
so currently, it would not be possible to specify what
TaU should be. We will, therefore, monitor what it is in
this feasibility trial and how this varies across CAMHS.
Our scoping study will be used to inform data collected,
and the duration of time that families spend within
CAMHS will be recorded. It is, nevertheless, expected
that CAMHS clinicians will be working in line with best
practice, as per the NICE guidelines for children with
CD [1]. In addition, in line with current best practice, it
is expected that practitioners delivering TaU will be in
receipt of supervision, and this will also be monitored as
part of the trial. CAPTs at sites will not provide mPCP,
non-manualised PCP, or TaU to dyads allocated to TaU
and will, therefore, have no contact with TaU
participants.
Both groups
All child and primary carer participants will be seen
within CAMHS. Clinicians in both arms of the trial will
have access to local Child Psychiatrists if medication or
hospitalisation needs to be considered for any of the
children participating in the trial. Routine care provided
outside CAMHS will be unaffected for both arms.
Data collection
Participant data
Participant assessments will be undertaken at the follow-
ing time points:
 Baseline (prior to randomisation)
 4 months post randomisation
 8 months post randomisation (for participants
recruited in the first 4 months of the trial).
A window of up to 2 weeks prior to randomisation will
be recommended for baseline data collection (ideally,
baseline and randomisation will occur on the same day)
and plus or minus 2 weeks from the target follow-up
date for outcome data. The feasibility of these windows
will be recorded (see Table 1).
At baseline and 4 months post randomisation, the
following questionnaires will be used:
 Child Behavior Checklist (CBCL and CBCL-TR)
[55, 56] (parental rating of child’s problem
behaviours and competencies, and teacher rating of
academic achievement and behaviour in class, in
addition to attendance and performance)
 General Health Questionnaire 12 (GHQ-12) [52]
(parental mental health)
 Parenting Stress Index (PSI) [57] (primary carer rating
of their own functioning, functioning of child, and
level of stress in the primary carer-child relationship)
 Beck Depression Inventory (BDI) (v2.0) [58]
(screening instrument for adult depressive
symptoms)
 Parental Reflective Functioning Questionnaire
(PRFQ) [59–61] (measure of reflective functioning)
 EuroQol 5 Dimensions (EQ-5D™) (3-level) [62]
(parental health-related quality of life)
 EuroQol 5 Dimensions Youth (EQ-5D-Y™) (3-level)
(to measure child’s health-related quality of life as
reported by the child via face-to-face researcher
administration when the child is able to report
for themselves, or by the primary carer as a
proxy-respondent where the child is unable or
unwilling to do so)
Questionnaires will be completed during researcher
visits to participants’ homes, or failing that, by telephone
or by post if necessary. Additionally, at baseline and at
4-month follow-up, the researcher will collect data from
the primary carer on:
 Current comorbid physical/mental health
 Current psychotropic medications (methylphenidate,
other specified)
 Current family composition (i.e. who the child
lives with)
At 8 months post randomisation, participants providing
data will be asked to complete specific measures (CBCL,
PRFQ, EQ-5D-Y) over the telephone in the first instance,
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or via a face-to-face visit or by post if necessary, to maxi-
mise follow-up data completion. The child’s school
teacher will be asked to complete the CBCL-TR by post at
baseline and 4 months post randomisation only.
Treatment and other data Baseline care provider data
will be collected from clinicians delivering treatment in
both arms of TIGA-CUB to provide details of the treat-
ing clinician’s job title, band, length of time working in
Table 1 Summary of assessments
Assessment (and involvement*) Timeline (months post randomisation)
Screening Baseline 4 months 8 months
Eligibility and consent
• Eligibility (inclusion criteria assessed by clinician) x x
• Consent (P) x
Background, demographics, interview data (C, P, R)
• Personal details (e.g. contact details) x
• Current comorbid physical/mental health x x x
• Psychotropic medications x x x
• Family composition x x x
• Difficulties since randomisation x x
Clinical data (P, R, CSO)
• Therapy details (CSO) x
• Therapist supervision details (therapist/supervisor) x
• Psychotropic medications details (CSO) x
• Referrals to other services (CSO) x
• Re-referrals to, or referrals within, CAMHS (CSO) x
• Baseline therapist data x
• Serious adverse event reporting Ongoing collection
Questionnaires
• AUDIT-C (P) x
• DAST-10 (P) x
• SDQ (P) x x
• EQ-5D-Y (P, proxy-completion and C, where able) x x x (just P)
• EQ-5D (P) x x
• CBCL (P) x x x
• CBCL-TRF (T) x x
• GHQ-12 (P) x x
• Parenting Stress Index (P) x x
• Beck Depression Inventory (P) x x
• Parental Reflective Functioning Questionnaire (P) x x x
• Healthcare Resource Use (P) x
Process evaluation
• Primary Carer Recruitment Feedback Questionnaire (P) x
• ‘End of trial’ survey (P) x
• Semi-structured interview (sample of P) x
• Child Psychotherapist Focus Groups (CAPT) **
*C child, P primary carer, R researcher, CSO clinical studies officer (from case notes), T teacher, CAPT child psychotherapist; **the focus group with CAPTs will be
conducted after the final sessions of CP have been delivered
AUDIT-C Alcohol-Use Disorders Identification Test, CBCL Child Behavior Checklist, CBCL-TRF Child Behavior Checklist-Teacher Report Form, DAST-10 Drug Abuse
Screening Test, EQ-5D EuroQol 5 Dimensions, EQ-5D-Y EuroQol 5 Dimensions Youth, GHQ-12 General Health Questionnaire, SDQ Strengths and
Difficulties Questionnaire
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CAMHS, professional qualifications and additional train-
ing in specific therapeutic techniques. The following
data covering the period from randomisation up to
4 months post randomisation will be collected from the
CAPTs/CAMHS team (or by the researcher or
authorised individuals from the research team with ap-
propriate access), and from the CAPT clinical
supervisors:
 Care pathway details (type, sessions offered and
attended, including sessions where participants did
not attend (DNAs) or could not attend (CNAs),
dates and duration of sessions, CAMHS
practitioners involved, family members involved, and
mutually agreed end date)
 Re-referrals to, or re-referrals within, CAMHS
 Referral to other services (including mental health,
social, criminal, education, etc.)
 A checklist of expected adverse events (based on
those listed in this protocol), with space to specify
others not listed
 Supervision details (intervention arm only).
All participants who enter TIGA-CUB will be considered
part of the intention-to-treat (ITT) population and efforts
will be made to follow them up whenever appropriate.
Process evaluation
The process evaluation aims to understand the function-
ing of the intervention and to inform the development
of a confirmatory trial protocol by identifying:
 Acceptability of recruitment processes, and reasons
for non-consent to trial participation
 Reasons for treatment dropout or withdrawal from
trial processes (i.e. from further data collection,
researcher follow-up visits or telephone or postal
questionnaire follow-up)
 Acceptability of data collection measures and timing
of data collection (i.e. burden)
 Possible adverse reactions to taking part in the trial
 CAPT, primary carer (and, if possible, child)
perspectives on aspects of the intervention
considered to be effective, and perceptions of
mechanisms of change
 Processes and challenges of implementing the
intervention from the perspective of the
CAPTs involved.
A questionnaire will be given to all eligible participants
during recruitment. Quantitative data will be collected
on primary carers’ characteristics, and on their views of
recruitment. At the end of the individual participant’s in-
volvement in the trial, a second brief questionnaire will
be sent to gather their views on taking part, on the inter-
vention or other treatment received, and on the trial
(except those participants withdrawing from postal ques-
tionnaires). If applicable, data will be collected on rea-
sons for treatment dropout and/or for withdrawing from
the trial. Free-text responses will be used to allow partic-
ipants to provide additional feedback about their experi-
ences of taking part in the trial, in addition to the closed
questions used in the survey.
Qualitative data on participants’ experiences of the
trial will be collected via semi-structured interviews.
Consent for interview will be obtained separately from
overall trial consent. Feedback will be sought from the
following groups:
 Decided against participation when trial presented
to them
 Agreed to participate in the trial and randomised
 Declined allocated treatment; dropped out of
treatment and/or withdrew from the trial (but not
the process evaluation).
In-depth, semi-structured qualitative interviews will be
conducted (to data saturation – expected to be about 15
primary carers). Purposive sampling will be used to en-
sure a wide range of primary carer views, including
where possible treatment completers, treatment drop-
outs, and those declining trial participation. For max-
imum variation, we will sample on child’s age and
gender, and degree of CBCL change, where possible. We
will also seek to recruit across centres to identify any
centre-level differences. Interviews will seek to maximise
understanding of the experiences of those taking part in
the trial and, where applicable, their views of the inter-
vention. Depending on age and willingness to partici-
pate, attempts will be made to gain some feedback from
children (what they liked or did not like), with their pri-
mary carer present.
A topic guide will be used to guide the interview dis-
cussion and will ask about why participants took part
(or not), the recruitment and randomisation process,
their experiences of participation, concerns about par-
ticipation, and burden of involvement. Interviews are
expected to last 45 to 60 min. Interviews will be under-
taken by a researcher with specific training and/or ex-
perience in conducting in-depth, exploratory interviews.
The timing of contact will vary between participant
groups:
 Those recruited within the first 3 months of the
recruitment period will be contacted after the
end of treatment and consent will be sought for
interview approximately 8 months after
randomisation, to capture longer-term views of
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the treatment and to assess the burden of data
completion on participants
 Those recruited within the last 4 months of the trial
will be contacted after, and interviewed within,
2 months of end of therapy to capture the
experiences of treatment and recruitment
 Those who decline trial involvement will be
contacted within a month of declining the trial.
All CAPTs taking part in the trial will be invited to
take part in a focus group discussion to talk about their
experiences of using mPCP. The focus group will take
place at the end of the trial once all dyads have com-
pleted mPCP. A topic guide will be used to explore
views about trial design, factors enabling or inhibiting
successful recruitment, intervention delivery, and data
collection. Participants will also be asked how mPCP fits
with their usual clinical practice, aspects of mPCP con-
sidered effective/perceived mechanisms of change, and
unanticipated or adverse impacts on services or dyads.
Health economics
This component is included to check the completeness
and ability to obtain resource-use data from dyads about
both NHS and private costs and quality of life. Wherever
possible, unit costs for resources will be obtained from
national sources such as the British National Formulary
(BNF) [63] and the Personal Social Services Research
Unit (PSSRU) Costs of Health and Social Care [64].
NHS and Social Service resource use will be identified
through direct observation of the treatment provided
within the feasibility trial and through the structured
questionnaire for collection of data on all other service
use. We will assess the level of completeness of EQ-5D-
Y as reported by the child and by the primary carer and
evaluate any discrepancies using Quality-adjusted Life
Years (QALYs) as the outcome.
Outcomes
Outcomes relate to feasibility of recruitment, therapeutic
delivery, retention in treatment, and outcome data
collection:
Recruitment methods, uptake, and follow-up: (1) num-
ber of dyads screened for eligibility, (2) proportion of
carers from eligible dyads consenting to the trial, (3)
proportion of consenting dyads randomised, (4) reasons
for non-participation, and (5) proportion of randomised
dyads completing the trial, number of withdrawals from
follow-up data collection, reasons for withdrawal, num-
ber of losses to follow-up.
Therapeutic delivery: (1) proportion of dyads rando-
mised to the intervention arm, proportion randomised
to, and seen by, the allocated CAPT; proportion of dyads
successfully completing the required number of mPCP
sessions specified in the manual; number of those dyads
where there was a mutually agreed earlier termination,
including reasons for early termination; early (non-
agreed) dropouts from the intervention, including
reasons for early dropout; (2) methods developed for
measuring dyad treatment attendance and CAPT adher-
ence to the manual, including the number of mPCP ses-
sions offered, attended, and missed, and evidence of the
appropriate use of the clinical approach advocated in the
intervention manual; (3) preliminary assessment of the ac-
ceptability of the intervention, including negative
outcomes, serious adverse events (SAEs), and related and
unexpected SAEs (RUSAEs) (all RUSAEs occurring from
the date of consent up to 4 (8, where applicable) months
post randomisation will be recorded, reviewed by the chief
investigator, and reported to the Research Ethics Committee
(REC) and the sponsor within 15 days; (4) mapping of the
range of standard care (CAMHS/external) pathways
across arms; and (5) number of patients where the
standard care pathway is known.
Follow-up data collection: (1) proportion of dyads with
self-reported outcome data, proportion obtained at
4 months (and 8 months if applicable); (2) proportion of
dyads with teacher-reported outcome data obtained at
baseline and 4 months; (3) proportion of dyads with self-
reported health economic data at 4 months; (4) propor-
tion of dyads for whom it was possible to collect routine
data, if this is pursued; (5) missing-item-level data on self-
reported questionnaires; and (6) number of unblinding
events of trial researchers over the data collection periods.
Statistical outcomes: (1) variability of self-reported
outcome measures at baseline, 4 months; (2) clustering
effect (ICC – intracluster correlation coefficient) relating
to CAPTs in the intervention arm; (3) difference in self-
reported outcomes available at 4 months per treatment
arm; and (4) 95% confidence intervals (CI) for differ-
ences in outcomes between arms.
Health economic outcomes: (1) variability of the self-
reported and proxy-reported EQ-5D-Y at baseline and
4 months; (2) completeness of and ability to obtain resource
use data from dyads about both NHS and private costs; (3)
exploratory cost-effectiveness analysis; and (4) suitability of
a decision analysis model and appropriate time horizon to
assess cost-effectiveness in the confirmatory RCT.
Process evaluation outcomes: (1) understanding of the
recruitment process (with ideas for improving recruit-
ment); (2) views on the intervention/trial; (3) reasons for
declining to take part, dropping out of treatment, or with-
drawing from the trial; (4) understanding of the contextual
factors affecting involvement in the trial; (5) understand-
ing of the barriers to, and enablers for, implementation;
and (6) understanding of possible mechanisms of change.
Qualitative: establishment of (1) processes for success-
ful recruitment of CAPTs; (2) procedure for training of
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CAPTs; (3) method for agreeing CAPT competence; and
(4) procedure for ongoing supervision of CAPTs.
Monitoring treatment attendance and adherence
Data will be collected on child and primary carer attend-
ance at sessions. The steps taken to ensure consistency
in the use of the mPCP intervention will also be re-
corded (attendance at training and supervision sessions
for CAPTs, adherence of CAPTs to the manual). Child
and primary carer mPCP intervention sessions will be
tape-recorded where consent for this has been obtained
from the primary carer, with the assent of the child.
CAPT supervision sessions will also be tape-recorded,
with consent. The chief investigator will review a selection
of the mPCP tape-recorded intervention and supervision
sessions to ensure, and allow reporting of, overall adher-
ence of CAPTs to the manual. We will develop a coding
and scoring system for assessing CAPT adherence to the
manual, with a global rating of overall adherence.
Sample size
The trial is designed to determine the feasibility of a
confirmatory trial, not to assess proof of concept or
evaluate effectiveness. It is generally recommended for
feasibility studies that the analysis data set comprises a
minimum of 30 participants per arm [65–67]. However,
based on a review of the academic literature [68–78], es-
timates of the standard deviation (SD) of CBCL total
score are already available, indicating that it is reason-
able to assume a common SD across arms. We therefore
require a minimum of 30 evaluable dyads across the
arms to confirm the SD. Loss to follow-up has ranged
from 8 to 38%, so we need up to 50 dyads randomised
to guarantee 30 evaluable dyads. Treatment attendance
has ranged from 40 to 95%. Assuming that we can re-
duce loss to follow-up to 10% at 4 months, randomising
60 dyads on a 1:1 basis will allow us to estimate the
pooled SD with a 95% CI with expected width of 0.39
multiplied by SD, loss to follow-up with a 95% CI with
expected width ± 7%, and treatment attendance in the
intervention arm with a 95% CI with expected width of
between ± 8 to 18%. It is expected that 60 dyads will pro-
vide sufficient opportunity to establish robust recruit-
ment and retention strategies for a confirmatory trial.
Statistical analysis
The trial statisticians will be responsible for statistical
analysis. The analysis plan outlined in this section will
be reviewed and a final, more detailed statistical analysis
plan will be written before any analysis is undertaken.
Any changes to the finalised analysis plan and reasons
for change will be documented. There are no planned
subgroup analyses. No formal analyses are planned until
after the trial is closed to recruitment and all patients
have been randomised. Final analysis will be carried out
when all available outcome data have been received.
The recruitment strategy will be evaluated by summar-
ising the screening, eligibility, consent, and randomisa-
tion stages, clearly separating the child from their
primary carer, including numbers of dyads involved dur-
ing each stage. Reasons for non-participation in the trial
will be summarised, dyad retention during follow-up, in-
cluding number of dyads completing/withdrawing from
the trial and reasons for withdrawal, will be presented
overall and by treatment arm.
Receipt of mPCP will be evaluated by summarising the
proportion of dyads attending at least one session and
those successfully completing the required amount of
mPCP as specified in the manual (or fewer, as deter-
mined by the CAPT), both individually and as a dyad.
The number of sessions and pattern of attendance will
also be summarised. The number of early mutually
agreed terminations and non-agreed dropouts from the
intervention arm will be reported and the reasons for
dropout summarised, where available. The method for
measuring mPCP treatment attendance by the dyad will
be agreed and summarised, i.e. number of sessions
attended and length of sessions attended by child and
primary carer, respectively, and a method for measuring
manual adherence will be developed, including CAPT at-
tendance at mPCP training, regular attendance and pres-
entation at clinical supervision, development of an
appropriate scoring system designed to assess manifest-
ation by CAPTs of key components of the manual, re-
view of a randomly selected subset of tape-recorded
child and primary carer mPCP sessions and CAPT
supervision sessions, employing this scoring system. The
range of co-interventions and TaU (in CAMHS) in both
arms will be summarised by treatment arm, as will refer-
rals outside of CAMHS. The feasibility of obtaining
information on care provided outside of the trial treat-
ments will be assessed by the number of dyads for which
this care is known, overall and by treatment arm.
The feasibility of obtaining the confirmatory trial’s pri-
mary and secondary outcome data will be assessed by
summarising the proportion of dyads with available self-
reported outcome data by method of obtainment, overall
and by treatment arm. Levels of, and where possible pre-
dictors of, missing self-reported outcome data, both at
the individual-item level and for entire outcome mea-
sures, will be reported overall and by treatment arm.
In order to inform the sample size/power calculation
for the confirmatory trial, we will assess the variability
(SD) of the CBCL total score in the intervention and
control arms to confirm the SD to be used. The clinic-
ally relevant difference will be assessed by establishing
the mean scores (and corresponding 95% CIs) of the
CBCL total score in the control arm and by seeking
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clinical opinion. Point and interval estimates of the eligi-
bility, recruitment, and treatment attendance rates in
this feasibility trial, along with the number of partici-
pants successfully followed up, will also help to inform
the sample size by allowing estimation of the likely loss
to follow-up rates that will occur, and will allow assess-
ment of the feasibility of recruitment for the confirma-
tory trial. An investigation of the clustering effect (ICC)
relating to the CAPTs will be carried out to aid sample
size calculation. The difference in outcomes between the
control and intervention arms at each point will be re-
ported, with 95% CIs constructed around these differ-
ences. No formal testing will be done on this data.
Health economic analysis
The health economist will be responsible for health eco-
nomic analysis. We will evaluate the completeness of
data and rate of missing data on individual questions to
inform the methodology and the perspective to be used
within the confirmatory trial. Although the cost-
effectiveness analysis at this stage will only be explora-
tory, the incremental cost-effectiveness of a second-line
mPCP intervention compared to TaU for children aged
5–11 years with treatment-resistant CD and their
primary carers will be examined. We will also calculate
indicative costs for the interventions.
Utility weights will be obtained from the EQ-5D-Y
data as reported by the child or by the primary carer as
a proxy-respondent for the child and collected as part of
the feasibility trial follow-up. We will also consider ag-
gregating utility gains, accumulating child and primary
carer utility obtained from the EQ-5D. An exploratory
cost-effectiveness analysis will be carried out on
complete cases only (i.e. completion at all time points)
and with imputations (multiple imputations based on
age, gender, and treatment), and a set of within-
feasibility trial sensitivity analyses will be undertaken.
Analysis for the process evaluation
A researcher with expertise in qualitative data analysis
will be responsible for analysis of the process evaluation.
Quantitative data from questionnaires will be analysed
using descriptive statistics to describe participant charac-
teristics, views on the intervention/trial, and reasons for
declining to take part, dropping out of treatment, or
withdrawing from the trial. Qualitative data will be ana-
lysed inductively using thematic analysis [79, 80] and
coded independently by two researchers for emerging
themes. The researchers will then compare codes and
themes and resolve any discrepancies by consensus. The
analysis will be further refined using constant compara-
tive and contrastive approaches, and examination of
negative cases. Data analysis will begin alongside data
collection in order to refine and develop the interview
topic guide(s) and sampling strategy, so that emerging
themes can be explored in greater depth. This early data
analysis will also help to identify when further data col-
lection is unlikely to yield any significant new themes
(i.e. ‘data saturation’ is reached), and so inform the num-
ber of primary carer/child interviews actually required.
Results will be used to optimise the information pro-
vided to participants about the trial to improve recruit-
ment and will inform the confirmatory trial design and
intervention delivery, e.g. changes to recruitment proce-
dures might be made in response to feedback from those
declining to take part.
Other analysis
Sessions from the intervention adherence monitoring
might additionally be transcribed and subject to further
exploratory analysis as part of MSc dissertation projects.
Ethical considerations
Ethical approval was granted for the trial by Yorkshire
and The Humber Bradford Leeds Research Ethics
Committee (Reference: 16/YH/0055). The right of par-
ticipants to refuse participation without giving reasons
will be respected and participants will remain free to
withdraw from the trial at any time without giving rea-
sons and without prejudicing further treatment. Primary
carers will make any such decision on behalf of the
child. The study protocol was written in line with
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Statement [81],
provided here as Additional file 1.
Trial governance
The Trial Management Group (TMG), comprising the
chief investigator, trial manager, co-investigators, and
CTRU team, will meet bi-monthly and will be respon-
sible for the clinical set-up, ongoing management and
interpretation of results. The Trial Steering Committee
(TSC), with an independent chair, will meet 6-monthly
and provide overall supervision of the project, including
trial progress, adherence to protocol, safety, and consid-
eration of new information.
Public and Patient Involvement (PPI)
Primary carers of children with CD and parents with
mental health difficulties provided input into the design
of the trial and both they and children with CD provided
input into trial-specific patient literature. Throughout
the trial, we will work with a PPI lay advisory group
(LAG) who will represent the needs of primary carers
and children with CD in the ongoing conduct of the
trial. Members of the LAG will also advise on promoting
the trial and disseminating results, and will be involved
in the interpretation of the qualitative results.
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Discussion
A series of success criteria have been set. If all of these
are met, the trial will be considered feasible with no re-
visions needed. If they are not met and revisions are not
possible, the trial will be considered unfeasible. If revi-
sions are needed but are possible, the suggested revisions
will be described in detail in the feasibility trial outputs.
The success criteria are as follows: (1) recruitment is feas-
ible, indicated by randomising to target; (2) treatment is
acceptable, indicated by qualitative feedback from primary
carers (and children, when possible) and from CAPTs; (3)
attendance at the mPCP intervention is acceptable, indi-
cated by child and primary carer, respectively, attending
more than 50% of the anticipated 12 sessions offered; (4)
data collection procedures for demonstrating manual ad-
herence are feasible, indicated by sessions recorded, ran-
dom subsets analysed, and qualitative feedback from
CAPTs; (5) data collection burden is acceptable to primary
carers, indicated by qualitative feedback; (6) missing data
is at an acceptable level, indicated by 75% of visits com-
pleted and minimal non-completion of questionnaires
within visits; and (7) estimates needed for the sample size
calculation obtainable.
We anticipate six main challenges in the delivery of
this project. First, outside of major centres, local com-
munity CAMHS are often overstretched clinically, and
relatively inexperienced in participating in RCTs. On-
going reviews of service provision and clinical pathways
have already led to one service, initially enthusiastic to
participate, withdrawing from the trial before its com-
mencement, as local service reorganisation meant a sig-
nificant reduction in capacity to provide a service to
children with CD. Delivering manualised protocols
against this backdrop will be a challenge and provide
valuable information about the feasibility of the larger
confirmatory trial.
Secondly, recruitment to the mPCP arm will be lim-
ited by CAPT availability. Although CAPTs are a core
profession in CAMHS in the Children’s National Service
Framework [82, 83], they are a relatively scarce resource
in the majority of CAMHS, and are likely to have only
very limited slots available for provision of the interven-
tion. Moreover, CAPTs work on a specific time scale
and do not usually commence an intervention less than
3–5 weeks prior to an end-of-term or half-term break in
order to avoid early interruption to the treatment. This
means that recruitment will need to occur within very
specific time frames. We will seek to maximise CAPT
availability through careful negotiation with participating
CAMHS and by drawing on CAMHS where there is
more than one CAPT, when possible. To avoid selection
bias, we plan to randomly allocate CAPTs to dyads allo-
cated to the intervention arm; however, doing so under
the constraints of CAPT capacity, variable numbers of
CAPTs per service, allocation of both child and primary
carer, and against the trial’s relative priorities, may intro-
duce further challenges.
A third challenge is likely to be retention of partici-
pants in treatment and/or in the research. As previously
stated, treatment dropout rates for this patient group are
likely to be high and collection of follow-up data might,
therefore, also be affected. We will seek to address treat-
ment dropout through the use of specific engagement
strategies in the mPCP intervention, and to minimise
loss to follow-up by emphasising to participants that
dropping out of treatment does not mean withdrawing
from the research.
Fourthly, with regard to the trial intervention, the de-
sign and length of mPCP has inevitably been affected by
financial limitations, and the majority of CAPTs are not
experienced with the use of manualised interventions. In
non-manualised PCP, CAPTs would usually expect to
see children and their primary carers for a longer (and,
therefore, more expensive) period. There is, therefore, a
question as to whether a confirmatory RCT would be a
fair trial of treatment. However, weekly work for primary
carers is often now the exception rather than the rule
(except when CAPTS are in training, when it is more
common), and, therefore, the intensity of the interven-
tion might mitigate the shortness of its duration.
Fifthly, identification of reliable, valid, non-interview-
based measures of attachment that can be practically
used in an RCT with limited finances is challenging [84].
Nevertheless, there are some early indications in the aca-
demic literature that parental reflective functioning
might correlate with child and adult attachment.
Finally, a ‘sleeper effect’ is often claimed for PCP [85],
and NICE has indicated that research is needed on
longer-term outcomes [1]. We would, therefore, ideally
like a minimum of 1-year follow-up in a confirmatory
trial. Given the financial constraints of this feasibility
study, however, we have opted for partial follow-up at
8 months post randomisation for the initial cohorts,
with a view to assessing the feasibility of longer-term
data collection.
A recent systematic review and meta-analysis evaluat-
ing the efficacy of non-pharmacological interventions for
CD in children and adolescents has found that most pre-
viously conducted RCTs are of very poor to fair quality
with small effect sizes [86]. It concludes that there is
insufficient evidence to support any one psychological
treatment (including parenting programmes) over an-
other for this patient group, and that future studies need
to provide detailed information about randomisation
and blinding arrangements, to triangulate parent-
reported measures, and to use full ITT analysis. There
are currently no ongoing or planned RCTs evaluating
mPCP for this patient group. The current trial is,
Edginton et al. Trials  (2017) 18:431 Page 13 of 16
therefore, an important step towards evaluating the ef-
fectiveness of a specific type of intervention (mPCP) not
usually researched by means of RCTs, and in investigat-
ing a much-needed, second-line intervention for this
hard-to-reach patient group.
Trial status
Recruitment of participants is ongoing in two trial dis-
tricts: one in Yorkshire, centred on the cities of Brad-
ford, Sheffield, and Wakefield, and the other in the West
Midlands, centred on Dudley and Walsall.
Additional file
Additional file 1: SPIRIT Checklist. (DOC 120 kb)
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